# RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib

> **NCT00410124** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 416 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** RAD001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00410124
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-02
- **Final completion:** 2011-10
- **Target enrollment:** 416 (ACTUAL)
- **Last updated:** 2013-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00410124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00410124, "RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00410124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*